Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

As physicians we take an oath to do no harm, yet are trapped providing care in a system that leaves patients confined and at ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF ...

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...